SCHEMBL1613540

SCHEMBL1613540

COc1cc(Br)cc2c1CCN2c1nc(N)ncc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ MAP3K14 Q99558 1/20 0.36
▸ RET P07949 1/20 0.35
▸ KIF5B P33176 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ DHFR P00374 2/20 0.34
▸ P2RX3 P56373 3/20 0.34
▸ P2RX2 Q9UBL9 3/20 0.34
▸ ROCK1 Q13464 1/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ HSP90B1 P14625 1/20 0.33
▸ TRAP1 Q12931 1/20 0.33
▸ GPR52 Q9Y2T5 2/20 0.33
▸ EGFR P00533 2/20 0.33
▸ PIK3CA P42336 1/20 0.32
▸ PDE10A Q9Y233 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12743405 0.83 RET (0.34) NPC1ALDH1A1HPGDRAB9ARXFP1
SCHEMBL1614154 0.77 MAP3K14 (0.38) NPC1RAB9AMAP3K14RETKIF5B
SCHEMBL1612018 0.75 MAP3K14 (0.60) NPC1ALDH1A1HPGDRAB9ARXFP1
SCHEMBL21880310 0.71 NPC1 (0.46) NPC1ALDH1A1HPGDRAB9ARXFP1
SCHEMBL1613738 0.70 TTBK1 (0.39) MAP3K14DHFRP2RX3P2RX2ROCK1
SCHEMBL1613330 0.67 ERN1 (0.36) ALDH1A1KDRP2RX3P2RX2PDE10A
SCHEMBL1613809 0.67 MAP3K14 (0.37) ALDH1A1MAP3K14ROCK1EGFRPIK3CA
SCHEMBL1612242 0.67 MAPT (0.36) KDRDHFRHSP90AA1
SCHEMBL1613305 0.66 MAP3K14 (0.38) ALDH1A1MAP3K14DHFRROCK1HSP90B1
SCHEMBL12714084 0.64 AKT1 (0.41) MAP3K14DHFRROCK1PIK3CATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2315751-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS Amgen Inc. (US) 2011-05-04 — — EP disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 — — US disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 — — US disclosed
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2011-04-14 — — US disclosed
WO-2009158011-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS AMGEN INC. (US) 2009-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086834-A1 ALKYNYL ALCOHOLS AS KINASE INHIBITORS NFKBIA, MAP3K1, MAP3K2 NPC1 778/4885ALDH1A1 1373/4885HPGD 989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback